Some 4-(2-fluorophenoxy)quinoline derivatives bearing a 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety 71 (Figure 37) were designed as c-Met inhibitors and evaluated against five c-Met-dependent cancer cell lines and one c-Met-independent cancer cell [80,81]. This evidence concerns the gene MET and cancer.